HOME >> MEDICINE >> NEWS
A leading cause of preventable blindness may be controlled by simple course of oral antibiotic

Treating entire communities with the oral antibiotic azithromycin might effectively control an infection that causes widespread eye disease in developing countries, according to a new study.

The eye disease is trachoma, one of the world's leading causes of preventable blindness. Research results show oral treatment to be markedly better in reducing the number of infections than topical therapy, which uses an ointment form of the antibiotic tetracycline. Public health programs historically used the topical ointment for treatment and control of trachoma.

"We have known for decades that we had the antibiotics to successfully treat this disease when cases developed, but we didn't seem to have the right drug delivery method to control the bug over time. Now we know that we do, and we are very excited at the promise of these results," said Julius Schachter, PhD, professor of laboratory medicine at the University of California San Francisco and lead investigator of the study.

"Although azithromycin costs more than tetracycline ointment, the expense may be offset by the higher costs of distributing and administering multiple doses of the ointment," added Schachter, who also is director of the UCSF Chlamydia Research Laboratory at San Francisco General Hospital Medical Center. Study findings are reported in the August 21st issue of the British medical journal, The Lancet.

Researchers compared the effect of the two antibiotic regimens on infection rates in villages located in trachoma endemic areas where transmission of infection is high. The villages were in the African countries of Egypt, The Gambia, and Tanzania.

Previous studies have shown that topical antibiotics reduced the severity of disease and infection levels for the short-term, but they did not control trachoma levels over the long-term.

Trachoma occurs when the bacterium Chlamydia trachomatis infects the inner eyelid. The disease persists in staggering numbers in developing countr
'"/>

Contact: Rebecca Sladek Nowlis
rsnowlis@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
20-Aug-1999


Page: 1 2 3

Related medicine news :

1. Public morally obliged to take part in scientific research, says leading ethicist
2. New guideline tackles leading cause of mother and child death
3. Breast implant Website launched by leading plastic surgery societies
4. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
5. Government approach to cutting hospital stays may be misleading
6. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
7. Money issues leading cause of holiday stress for Americans
8. Tar measurements on cigarette packets are misleading
9. Researchers discover new clinical syndrome leading to severe osteoarthritis
10. Lung cancer now leading cause of cancer death in women
11. Mechanism leading to life-threatening infection identified by UCSD School of Medicine researchers

Post Your Comments:
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
Cached News: